Results 41 to 50 of about 235,245 (306)

Unbreakable codes in electrospun fibers : digitally encoded polymers to stop medicine counterfeiting [PDF]

open access: yes, 2010
Fluorescent polymer solutions can easily be electrospun into micrometer-sized fibers and subsequently encoded with long lasting digital codes by a photobleaching process.
Braeckmans, Kevin   +9 more
core   +2 more sources

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson   +3 more
wiley   +1 more source

RNA Virus Evolution via a Quasispecies-Based Model Reveals a Drug Target with a High Barrier to Resistance

open access: yesViruses, 2017
The rapid occurrence of therapy-resistant mutant strains provides a challenge for anti-viral therapy. An ideal drug target would be a highly conserved molecular feature in the viral life cycle, such as the packaging signals in the genomes of RNA viruses ...
Richard J. Bingham   +2 more
doaj   +1 more source

Now I can feel myself! [PDF]

open access: yes, 2010
This paper addresses the visual discourse of psychopharmaceuticals, such as Prozac, in order to investigate the network of relationships of affects, advertising, design and the production of new identity practices.
Marenko, Betti
core  

Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle   +5 more
wiley   +1 more source

Pharmaceutical compounding of orphan active ingredients in Belgium : how community and hospital pharmacists can address the needs of patients with rare diseases [PDF]

open access: yes, 2019
Background: Pharmaceutical compounding of orphan active ingredients can offer cost-effective treatment to patients when no other drug product is available for a rare disease or during periods of drug product shortages.
Boussery, Koen   +7 more
core   +2 more sources

NRASQ61R Expression in Lymphatic Endothelial Cells Causes Enlarged Vessels, Hemorrhagic Chylous Effusions, and High Mortality in a Mouse Model of Kaposiform Lymphangiomatosis

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Kaposiform lymphangiomatosis (KLA) is an aggressive complex lymphatic anomaly. Patients exhibit malformed lymphatic vessels and often develop hemorrhagic effusions and elevated angiopoietin‐2 (Ang‐2) levels. A somatic NRAS p.Q61R (NRASQ61R) mutation has been associated with KLA.
C. Griffin McDaniel   +3 more
wiley   +1 more source

Pharmaceutical Packaging Materials and Medication Safety: A Mini-Review

open access: yesSafety
Pharmaceutical packaging materials play a crucial role in ensuring the safety and efficacy of medications. This mini-review examines the properties of common packaging materials (glass, plastics, metals, and rubber) and their implications for drug safety.
Yaokang Lv   +4 more
doaj   +1 more source

Translating extracellular vesicle packaging into therapeutic applications

open access: yesFrontiers in Immunology, 2022
Extracellular vesicles (EVs) are membrane-bound particles released by cells in various (patho)physiological conditions. EVs can transfer effector molecules and elicit potent responses in recipient cells, making them attractive therapeutic agents and drug
Dilara C. Ozkocak   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy